Singapore’s PRECISE program announced precompetitive partnerships with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from its PRECISE‑SG100K cohort. The collaboration will combine whole‑genome and proteomic (SomaScan 11K) datasets to drive population‑specific research and accelerate Asian‑centric biomarker and target discovery. PRECISE framed the deal as a way to close major diversity gaps in genomic research and to create translational hypotheses for diagnostics and therapeutics tailored to Asian populations, while industrial partners gain access to high‑quality multi‑omic datasets for preclinical and early‑clinical research.